Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.